Nonalcoholic fatty liver disease from the perspective of an internist

Ochsner Journal

Volumn 4, Issue 2, 2002, Pages 92-97

  Nair, Satheesh ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; BETAINE; ESTROGEN; METFORMIN; TROGLITAZONE; URSODEOXYCHOLIC ACID;

ANIMAL MODEL; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; EPIDEMIOLOGICAL DATA; FATTY LIVER; HUMAN; INCIDENCE; INSULIN RESISTANCE; INTERNAL MEDICINE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MEDICAL SPECIALIST; MOUSE; NONHUMAN; OBESITY; PATHOGENESIS; WEIGHT REDUCTION;

EID: 0036300692     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease
2. Steatohepatitis: A tale of two "hits"?
3. Nonalcoholic steatohepatitis
4. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation
5. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
6. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis
7. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes
8. Obesity and female gender increase breath ethanol concentration: Potential implications for the pathogenesis of nonalcoholic steatohepatitis
9. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
10. Non alcoholic fatty liver disease: The most common cause of abnormal liver enzymes in the US population
11. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
12. Prevalence of and risk factors for hepatic steatosis in Northern Italy
13. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study
14. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
15. Frequency of non-alcoholic steatohepatitis as a cause of advanced liver disease
16. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
17. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese
18. Relative Risk of Hepatocellular Carcinoma in Cirrhosis due to Fatty Liver Disease: A Study Based on Incidental Hepatocellular Carcinoma in Liver Transplant Recipient
19. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients
20. Metformin reverses fatty liver disease in obese, leptin-deficient mice
21. Metformin in non-alcoholic steatohepatitis
22. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis
23. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study
24. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study
25. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study
26. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
27. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis